JPS531190B2
(es)
|
1974-02-22 |
1978-01-17 |
|
|
NL7605526A
(nl)
|
1976-05-24 |
1977-11-28 |
Akzo Nv |
Nieuwe tetracyclische derivaten.
|
US4154836A
(en)
|
1976-05-24 |
1979-05-15 |
Akzona Incorporated |
Tension reducing 1,2,3,4,4a,13b-hexahydro-dibenz[2,3;6,7]oxepino[4,5-c]pyridines
|
JPS61502751A
(ja)
*
|
1984-07-23 |
1986-11-27 |
シエリング,コ−ポレ−シヨン |
アザタジンの経度デリバリ−
|
US5656286A
(en)
*
|
1988-03-04 |
1997-08-12 |
Noven Pharmaceuticals, Inc. |
Solubility parameter based drug delivery system and method for altering drug saturation concentration
|
US5446070A
(en)
|
1991-02-27 |
1995-08-29 |
Nover Pharmaceuticals, Inc. |
Compositions and methods for topical administration of pharmaceutically active agents
|
US5474783A
(en)
|
1988-03-04 |
1995-12-12 |
Noven Pharmaceuticals, Inc. |
Solubility parameter based drug delivery system and method for altering drug saturation concentration
|
EP0387751B1
(en)
|
1989-03-15 |
1994-06-08 |
Nitto Denko Corporation |
Medicated plasters
|
DE3937271A1
(de)
|
1989-11-09 |
1991-05-16 |
Boehringer Ingelheim Kg |
Transdermale applikation von 2-amino-6-n-propylamino-4,5,6,7-tetrahydrobenzothiazol
|
EP0569096A1
(en)
|
1992-05-08 |
1993-11-10 |
Akzo Nobel N.V. |
Depot preparation
|
NZ282394A
(en)
|
1994-03-02 |
1997-12-19 |
Akzo Nobel Nv |
Dissolving tablets contain a dibenz[2,3:6,7] oxepino[4,5-c]pyrrole derivative for sublingual or buccal administration
|
JP3274579B2
(ja)
|
1995-01-12 |
2002-04-15 |
住友製薬株式会社 |
脳血管障害に伴う精神症候治療剤
|
KR100213465B1
(ko)
|
1996-11-01 |
1999-08-02 |
최좌진 |
케토프로펜 패취 조성물
|
TR199902727T2
(xx)
|
1997-05-26 |
2000-07-21 |
Akzo Nobel N.V. |
Aromatik s�lfonik asitlerin tuzlar�.
|
US7150881B2
(en)
|
1997-06-26 |
2006-12-19 |
Mylan Technologies, Inc. |
Adhesive mixture for transdermal delivery of highly plasticizing drugs
|
GB9714650D0
(en)
|
1997-07-11 |
1997-09-17 |
Strakan Ltd |
Block copolymer
|
WO1999032108A1
(en)
|
1997-12-19 |
1999-07-01 |
Akzo Nobel N.V. |
Org-5222 in the treatment of depression
|
DE19814083C2
(de)
|
1998-03-30 |
2002-02-07 |
Lohmann Therapie Syst Lts |
Verfahren zur Herstellung von transdermalen therapeutischen Systemen unter Verwendung von basischen Alkalimetallsalzen zur Umwandlung von Wirkstoffsalzen in die freien Basen
|
NZ509655A
(en)
|
1998-07-29 |
2002-09-27 |
Teijin Ltd |
Pressure sensitive adhesive composition containing an acrylic adhesive agent and a polyhydric alcohol and moisture-permeable pressure-sensitive adhesive tape thereof
|
US20040142024A1
(en)
|
1999-07-27 |
2004-07-22 |
Hisamitsu Pharmaceutical Co., Inc. |
Patch formulation for external use
|
WO2001052823A2
(en)
|
2000-01-20 |
2001-07-26 |
Noven Pharmaceuticals, Inc. |
Compositions to effect the release profile in the transdermal administration of drugs
|
AU1436402A
(en)
|
2000-11-06 |
2002-05-15 |
Samyang Corp |
Transdermal drug delivery system with improved water absorbability and adhesion properties
|
AU2002232470B2
(en)
|
2001-01-02 |
2005-11-03 |
Pharmacia & Upjohn Company Llc |
New drug combinations of norepinehrine reuptake inhibitors and neuroleptic agents
|
EP1366762B1
(en)
|
2001-03-07 |
2015-12-30 |
Hisamitsu Pharmaceutical Co., Inc. |
Adhesive patch
|
WO2002087590A1
(en)
|
2001-04-26 |
2002-11-07 |
Ortho-Mcneil Pharmaceutical, Inc. |
Treatment of psychotic disorders comprising co-therapy with anticonvulsant derivatives and atypical antipsychotics
|
GB0119012D0
(en)
|
2001-08-03 |
2001-09-26 |
Strakan Group Plc |
Transdermal delivery of drugs
|
JP4323138B2
(ja)
|
2002-06-05 |
2009-09-02 |
日東電工株式会社 |
経皮吸収型製剤およびその製造方法
|
MXPA05000294A
(es)
|
2002-07-30 |
2005-08-19 |
Peter Migaly |
Terapia combinada para la depresion, prevencion de suicidios y varias condiciones medicas y psiquiatricas.
|
DK1530469T3
(da)
*
|
2002-08-20 |
2009-05-04 |
Euro Celtique Sa |
Transdermal dosisform omfattende et aktivt middel og et salt og fri baseform af en antagonist
|
WO2004098472A1
(en)
|
2002-08-30 |
2004-11-18 |
Watson Pharmaceuticals, Inc. |
Transdermal delivery systems and methods
|
AU2003284899A1
(en)
|
2002-10-29 |
2004-05-25 |
Miicro, Inc. |
Novel combination therapy for schizophrenia focused on improved cognition: 5-ht-2a/d2 blockade with adjunctive blockade of prefrontal da reuptake
|
GB0302662D0
(en)
|
2003-02-05 |
2003-03-12 |
Strakan Ltd |
Transdermal granisetron
|
GB0306604D0
(en)
|
2003-03-21 |
2003-04-30 |
Curidium Ltd |
Second medical use
|
MXPA05012317A
(es)
|
2003-05-16 |
2006-01-30 |
Pfizer Prod Inc |
Combinaciones terapeuticas de agentes antipsicoticos atipicos con agentes moduladores del gaba anticonvulsivos o benzodiazepinas.
|
TWI327915B
(en)
|
2003-06-12 |
2010-08-01 |
Organon Nv |
Pharmaceutical composition comprising antipsychotic agent and use of the antipsychotic agent for treating patients with overweight
|
US20080020028A1
(en)
*
|
2003-08-20 |
2008-01-24 |
Euro-Celtique S.A. |
Transdermal dosage form comprising an active agent and a salt and a free-base form of an adverse agent
|
EP1684681B1
(en)
|
2003-10-10 |
2018-10-24 |
Oryxe |
A mixture for transdermal delivery of low and high molecular weight compounds
|
AU2004285505B2
(en)
|
2003-10-28 |
2010-12-23 |
Noven Pharmaceuticals, Inc. |
Transdermal drug delivery device
|
CA2546200A1
(en)
|
2003-11-18 |
2005-06-02 |
3M Innovative Properties Company |
Olanzapine containing transdermal drug delivery compositions
|
PL1708790T3
(pl)
|
2003-12-02 |
2010-10-29 |
Pharmaneuroboost N V |
Zastosowanie pipamperonu oraz antagonisty receptora D2 lub antagonisty receptora serotoniny/dopaminy do leczenia zaburzeń psychotycznych
|
EP1576985A1
(en)
|
2004-03-18 |
2005-09-21 |
B&B Beheer NV |
Use of D4 and 5-HT2A antagonists, inverse agonists or partial agonists
|
US7884096B2
(en)
|
2003-12-02 |
2011-02-08 |
Pharmaneuroboost N.V. |
Method of treating mental disorders using of D4 and 5-HT2A antagonists, inverse agonists or partial agonists
|
EP1547650A1
(en)
|
2003-12-02 |
2005-06-29 |
B & B Beheer NV |
Use of D4 and 5-HT2A antagonists, inverse agonists or partial agonists
|
JP2007516275A
(ja)
|
2003-12-23 |
2007-06-21 |
ファイザー・プロダクツ・インク |
認知増強および精神病性障害のための治療的組合せ
|
JP2007519705A
(ja)
|
2004-01-29 |
2007-07-19 |
ファイザー・プロダクツ・インク |
Cns障害を治療するための非定型抗精神病薬とアミノメチルピリジルオキシメチル/ベンゾイソオキサゾールアザビシクロ誘導体の組合せ
|
CN1917882A
(zh)
|
2004-02-13 |
2007-02-21 |
辉瑞产品公司 |
非典型抗精神病药物与促肾上腺皮质激素释放因子拮抗剂的治疗剂组合
|
US7650848B2
(en)
|
2004-02-17 |
2010-01-26 |
University Of Florida Research Foundation, Inc. |
Surface topographies for non-toxic bioadhesion control
|
JP2007526328A
(ja)
|
2004-03-02 |
2007-09-13 |
ファルマシア コーポレーション |
単独および抗うつ薬と組み合わせた形のCox−2阻害剤によって精神障害を治療または予防するための方法および組成物
|
GB0405200D0
(en)
|
2004-03-08 |
2004-04-21 |
Pfizer Ltd |
Combinations comprising alpha-2-delta ligands
|
US9205062B2
(en)
|
2004-03-09 |
2015-12-08 |
Mylan Pharmaceuticals, Inc. |
Transdermal systems containing multilayer adhesive matrices to modify drug delivery
|
JP4961207B2
(ja)
|
2004-04-21 |
2012-06-27 |
久光製薬株式会社 |
粘着基剤中の吸収促進剤の含有率を高めた外用貼付剤
|
RU2445095C2
(ru)
|
2004-04-22 |
2012-03-20 |
Бёрингер Ингельхайм Интернациональ Гмбх |
Новые фармацевтические композиции для лечения сексуальных расстройств
|
BRPI0510942A
(pt)
|
2004-05-11 |
2007-07-17 |
Pfizer Prod Inc |
combinação de antipsicóticos atìpicos e antagonistas do receptor 5-ht1b
|
WO2006000222A2
(en)
|
2004-06-24 |
2006-01-05 |
H. Lundbeck A/S |
The combination of an antipsychotic and a glycine transporter type i inhibitor for the treatment of schizophrenia
|
US20060019969A1
(en)
|
2004-07-24 |
2006-01-26 |
Laboratorios Dr. Esteve S.A. |
Use of compounds active on the sigma receptor for the treatment of allodynia
|
ITMI20041628A1
(it)
|
2004-08-06 |
2004-11-06 |
Bouty S P A |
Sistema terapeutico a rilascio controllato per uso topico transdermico
|
GB0417702D0
(en)
|
2004-08-09 |
2004-09-08 |
Merck Sharp & Dohme |
New uses
|
US20060039869A1
(en)
*
|
2004-08-17 |
2006-02-23 |
Daniel Wermeling |
Intranasal delivery of antipsychotic drugs
|
US20060078602A1
(en)
|
2004-10-08 |
2006-04-13 |
Noven Pharmaceuticals, Inc. |
Device for transdermal administration of drugs including acrylic polymers
|
CA2583340C
(en)
|
2004-10-08 |
2015-09-08 |
Noven Pharmaceuticals, Inc. |
Transdermal drug delivery device including an occlusive backing
|
KR20070084123A
(ko)
|
2004-10-15 |
2007-08-24 |
엔.브이.오가논 |
양극성 장애 및 관련 증상의 치료
|
ES2317138T3
(es)
|
2004-11-22 |
2009-04-16 |
Hisamitsu Pharmaceutical Co., Inc. |
Parche transdermico que comprende un agente de diminucion del punto de fusion.
|
US20060150989A1
(en)
|
2005-01-12 |
2006-07-13 |
Peter Migaly |
Method of diagnosing, treating and educating individuals with and/or about depression
|
KR20070096058A
(ko)
|
2005-01-28 |
2007-10-01 |
쉬바르츠파르마에이지 |
정신분열증의 부가 요법용 spm 927
|
JP5084496B2
(ja)
|
2005-02-04 |
2012-11-28 |
久光製薬株式会社 |
経皮吸収貼付剤
|
RU2007132865A
(ru)
|
2005-03-01 |
2009-03-10 |
Пфайзер Лимитед (GB) |
Применение ингибиторов pde7 для лечения невропатической боли
|
WO2006096439A2
(en)
|
2005-03-04 |
2006-09-14 |
Boehringer Ingelheim International Gmbh |
Pharmaceutical compositions for the treatment and/or prevention of schizophrenia and related diseases
|
GB0506139D0
(en)
*
|
2005-03-24 |
2005-05-04 |
Transphase Ltd |
A transdermal topical composition and its uses
|
EP1710241B1
(en)
|
2005-04-07 |
2009-11-04 |
N.V. Organon |
Intermediate compounds for the preparation of trans-5-chloro-2-methyl-2,3,3a,12b-tetrahydro-1h-dibenz[2,3:6,7]oxepino[4,5-c]pyrrole
|
ES2293626T3
(es)
|
2005-04-07 |
2008-03-16 |
N.V. Organon |
Forma cristalina del maleato de asenapina.
|
US7872147B2
(en)
|
2005-04-07 |
2011-01-18 |
N. V. Organon |
Intermediate compounds for the preparation of trans-5-chloro-2-methyl-2,3,3a,12b-tetrahydro-1H-dibenz[2,3:6,7]oxepino[4,5-c]pyrrole
|
US7741358B2
(en)
|
2005-04-14 |
2010-06-22 |
N.V. Organon |
Crystal form of asenapine maleate
|
JPWO2006118212A1
(ja)
|
2005-04-27 |
2008-12-18 |
株式会社 ユーエムエヌファーマ |
膵炎の予防および治療剤
|
EP1731143B1
(en)
|
2005-06-06 |
2008-11-26 |
Nitto Denko Corporation |
Percutaneous absorption-type pharmaceutical preparation using a metal chloride, preferably sodium chloride, for preventing cohesive failure
|
CA2548864C
(en)
|
2005-06-06 |
2012-12-11 |
Nitto Denko Corporation |
Percutaneous absorption-type pharmaceutical preparation
|
JP5000932B2
(ja)
|
2005-06-21 |
2012-08-15 |
日東電工株式会社 |
ニコチン含有経皮吸収製剤
|
US20070015763A1
(en)
|
2005-07-12 |
2007-01-18 |
Pfizer Inc |
Treatment of psychosis associated with parkinson's disease and subcortical dementias using a combination of an atypical antipsychotic with a dopamine agonist
|
WO2007017750A1
(en)
|
2005-08-08 |
2007-02-15 |
Pfizer Products Inc. |
Benzoate salt of 4-(5-methyl-oxazolo[4,5-b]pyridin-2-yl)-1,4-diaza-bicyclo[3.2.2]nonane
|
DE102005050431A1
(de)
|
2005-10-21 |
2007-04-26 |
Lts Lohmann Therapie-Systeme Ag |
Transdermales therapeutisches System zur Verabreicherung lipophiler und/oder wenig hautpermeabler Wirkstoffe
|
WO2007046554A1
(ja)
|
2005-10-21 |
2007-04-26 |
Sumitomo Chemical Company, Limited |
ジベンゾオキセピノピロール化合物の製造方法、その中間体及び該中間体の製造方法
|
US7888422B2
(en)
|
2005-11-09 |
2011-02-15 |
Mylan Technologies Inc. |
Long-wearing removable pressure sensitive adhesive
|
TWI389709B
(zh)
*
|
2005-12-01 |
2013-03-21 |
Novartis Ag |
經皮治療系統
|
JP5037831B2
(ja)
|
2006-02-15 |
2012-10-03 |
久光製薬株式会社 |
凝集力向上及び徐放化の外用貼付剤
|
CN101410096A
(zh)
|
2006-03-27 |
2009-04-15 |
万能药生物有限公司 |
基于包含酸溶性聚合物和ph非依赖性聚合物的释放系统的持续释放药物组合物
|
TW200812993A
(en)
|
2006-05-02 |
2008-03-16 |
Lundbeck & Co As H |
New uses of escitalopram
|
US20070259952A1
(en)
|
2006-05-02 |
2007-11-08 |
H. Lundbeck A/S |
Uses of escitalopram
|
WO2007137224A2
(en)
|
2006-05-22 |
2007-11-29 |
Vanda Pharmaceuticals, Inc. |
Method of treatment
|
US8354121B2
(en)
|
2006-06-09 |
2013-01-15 |
Dainippon Sumitomo Pharma Co., Ltd. |
Tape preparation
|
TW200817414A
(en)
|
2006-07-05 |
2008-04-16 |
Organon Nv |
Process for the preparation of asenapine and intermediate products used in said process
|
US7750167B2
(en)
|
2006-07-05 |
2010-07-06 |
N.V. Organon |
Process for the preparation of asenapine and intermediate products used in said process
|
CN101506172A
(zh)
|
2006-07-14 |
2009-08-12 |
辉瑞产品公司 |
(7S)-7-[(5-氟-2-甲基-苄基)氧基]-2-[(2R)-2-甲基哌嗪-1-基]-6,7-二氢-5H-环戊烷并[b]吡啶的酒石酸盐
|
US20080045512A1
(en)
|
2006-08-09 |
2008-02-21 |
Pfizer Inc. |
Benzoate salt of 4-(5-methyl-oxazolo[4,5-b]-pyridin-2-yl)-1,4-diazabicyclo[3.2.2]nonane
|
CA2667668A1
(en)
|
2006-10-06 |
2008-04-10 |
N.V. Organon |
Amorphous asenapine and processes for preparing same
|
DE102006050558B4
(de)
*
|
2006-10-26 |
2009-03-26 |
Lts Lohmann Therapie-Systeme Ag |
Transdermales therapeutisches System enthaltend Norelgestromin zur Kontrazeption und Hormonsubstitution
|
EP2638906A1
(en)
|
2006-12-01 |
2013-09-18 |
Nitto Denko Corporation |
Stabilized adhesive preparation containing donepezil
|
BRPI0719307A2
(pt)
|
2006-12-01 |
2014-02-04 |
Nitto Denko Corp |
Método para a supressão da descoloração ao longo do tempo da preparação adesiva contendo donepezil.
|
CN101563312A
(zh)
|
2006-12-22 |
2009-10-21 |
住友化学株式会社 |
阿塞那平合成中间体的制备方法
|
US7875729B2
(en)
|
2007-01-05 |
2011-01-25 |
Synthon Bv |
Process for making asenapine
|
EP2494967A1
(en)
|
2007-01-16 |
2012-09-05 |
Ipintl, Llc |
Novel composition for treating metabolic syndrome
|
US20080226698A1
(en)
|
2007-03-16 |
2008-09-18 |
Mylan Technologies, Inc. |
Amorphous drug transdermal systems, manufacturing methods, and stabilization
|
FR2913882B1
(fr)
|
2007-03-20 |
2009-05-01 |
Oreal |
Utilisation pour la coloration des fibres keratiniques d'une composition comprenant un compose halochromique et/ou le colorant correspondant a ce compose
|
WO2008141438A1
(en)
|
2007-05-17 |
2008-11-27 |
Sunnybrook Health Sciences Centre |
Gabaergic modulators for treating airway conditions
|
WO2008148515A1
(en)
|
2007-06-05 |
2008-12-11 |
Synthon B.V. |
Intranasal administration of asenapine and pharmaceutical compositions therefor
|
WO2009000890A2
(en)
|
2007-06-27 |
2008-12-31 |
N.V. Organon |
Medication container
|
JP5245428B2
(ja)
|
2007-07-06 |
2013-07-24 |
住友化学株式会社 |
トランス−ジベンゾオキセノピロール化合物の製造方法およびその中間体
|
US20100178323A1
(en)
|
2007-07-10 |
2010-07-15 |
Agis Kydonieus |
Dermal Delivery Device
|
JP5224163B2
(ja)
|
2007-07-24 |
2013-07-03 |
コスメディ製薬株式会社 |
経皮吸収テープ製剤
|
WO2009017453A1
(en)
|
2007-07-30 |
2009-02-05 |
Astrazeneca Ab |
New therapeutic combination of an antipsychotic and a gsk3 inhibitor 958
|
CN101842010A
(zh)
|
2007-08-01 |
2010-09-22 |
梅迪维新神经学公司 |
使用抗精神病的组合治疗产品来治疗精神分裂症的方法和组合物
|
US20090209608A1
(en)
|
2007-08-29 |
2009-08-20 |
Protia, Llc |
Deuterium-enriched asenapine
|
US8652776B2
(en)
|
2007-09-10 |
2014-02-18 |
Vanda Pharmaceuticals, Inc. |
Prediction of QT prolongation based on SNP genotype
|
WO2009036056A1
(en)
|
2007-09-10 |
2009-03-19 |
Vanda Pharmaceuticals, Inc. |
Antipsychotic treatment based on snp genotype
|
WO2009035473A2
(en)
|
2007-09-13 |
2009-03-19 |
Sanfilippo Louis C |
Method of treating binge eating disorder, obesity resulting from binge eating behavior and depressive disorders
|
US20100297181A1
(en)
|
2007-12-26 |
2010-11-25 |
Eisai R&D Management Co., Ltd. |
AMPA Receptor Antagonists for Epilepsy, Mental Disorders or Deficits in Sensory Organ
|
MX2010007404A
(es)
|
2008-01-04 |
2010-10-05 |
Organon Nv |
Procedimiento para la preparacion de asenapina y productos intermediarios utilizados en dicho procedimiento.
|
GB2456183A
(en)
|
2008-01-04 |
2009-07-08 |
Gw Pharma Ltd |
Anti-psychotic composition comprising cannabinoids and anti-psychotic medicament
|
US8529441B2
(en)
*
|
2008-02-12 |
2013-09-10 |
Innurvation, Inc. |
Ingestible endoscopic optical scanning device
|
MX2010008875A
(es)
|
2008-02-13 |
2010-08-31 |
Targacept Inc |
Agonistas nicotinicos alfa 7 y antipsicoticos.
|
WO2009107479A1
(ja)
|
2008-02-27 |
2009-09-03 |
久光製薬株式会社 |
貼付製剤
|
US8741861B2
(en)
|
2008-03-27 |
2014-06-03 |
Vascular Biosciences |
Methods of novel therapeutic candidate identification through gene expression analysis in vascular-related diseases
|
JP5301190B2
(ja)
|
2008-03-31 |
2013-09-25 |
積水メディカル株式会社 |
貼付剤
|
WO2009135091A1
(en)
|
2008-04-30 |
2009-11-05 |
Medivation Technologies, Inc. |
Use of asenapine and related compounds for the treatment of neuronal or non-neuronal diseases or conditions
|
CN102099020B
(zh)
|
2008-05-30 |
2013-09-18 |
迈兰股份有限公司 |
稳定的透皮药物递送系统
|
NZ588311A
(en)
|
2008-07-24 |
2012-08-31 |
Handa Pharmaceuticals Llc |
Stabilized atypical antipsychotic formulation to treat psychiatric conditions
|
ES2546732T3
(es)
|
2008-08-20 |
2015-09-28 |
Brainco Biopharma, S.L. |
STXBP1 como biomarcador psiquiátrico en un sistema de modelo murino y sus usos
|
MX2011002177A
(es)
|
2008-09-04 |
2011-04-12 |
Neurosearch As |
Metodo para combatir efectos adversos que surgen del tratamiento antipsicotico.
|
WO2010060742A1
(en)
|
2008-11-03 |
2010-06-03 |
Solvay Pharmaceuticals B.V. |
Combination of bifeprunox and an antipsychotic drug with d2/5-ht2a receptor antagonistic activity for treating cns disorders
|
WO2010073326A1
(ja)
|
2008-12-24 |
2010-07-01 |
ニチバン株式会社 |
経皮吸収型製剤
|
WO2010080757A2
(en)
|
2009-01-07 |
2010-07-15 |
Astrazeneca Ab |
Combinations with an alpha-4beta-2 nicotinic agonist
|
ES2615884T3
(es)
|
2009-01-20 |
2017-06-08 |
Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center |
Ácido sórbico y benzoico y sus derivados que aumentan la actividad de un neurofármaco
|
US9561352B2
(en)
|
2009-03-12 |
2017-02-07 |
Delpor, Inc. |
Implantable device for long-term delivery of drugs
|
US8579865B2
(en)
|
2009-03-20 |
2013-11-12 |
Antares Pharma, Inc. |
Hazardous agent injection system
|
WO2010110914A2
(en)
|
2009-03-27 |
2010-09-30 |
Zirus, Inc. |
Mammalian genes involved in infection
|
EP2236138A1
(en)
|
2009-03-30 |
2010-10-06 |
PharmaNeuroBoost N.V. |
Low dose pipamperone in treating mood and anxiety disorders
|
EP2236157A1
(en)
|
2009-03-30 |
2010-10-06 |
PharmaNeuroBoost N.V. |
Pipamperone and a second agent in treating mood and anxiety disorders
|
CA2757144A1
(en)
|
2009-03-30 |
2010-10-07 |
Pharmaneuroboost N.V. |
Low dose pipamperone in treating mood disorders
|
WO2010119455A2
(en)
|
2009-04-15 |
2010-10-21 |
Sun Pharma Advanced Research Company Ltd. |
An injectable sustained release pharmaceutical composition
|
JP2012524112A
(ja)
|
2009-04-21 |
2012-10-11 |
サノミューン・インコーポレイテッド |
統合失調症および双極性障害を治療するための組織カリクレイン
|
TWI471127B
(zh)
|
2009-04-29 |
2015-02-01 |
Intervet Int Bv |
供人類使用之口服崩解錠劑的製備方法、所製得之口服崩解錠劑、以及含有該口服崩解錠劑的包裝物
|
TWI552773B
(zh)
|
2009-05-01 |
2016-10-11 |
久光製藥股份有限公司 |
經皮吸收型製劑
|
WO2010127674A1
(en)
*
|
2009-05-06 |
2010-11-11 |
Sunin K/S |
Transdermal compositions of asenapine for the treatment of psychiatric disorders
|
RU2012102247A
(ru)
|
2009-06-24 |
2013-07-27 |
Мсд Осс Б.В. |
Инъекционные композиции, содержащие асенапин и способ лечения с их применением
|
US20110306596A1
(en)
|
2009-07-27 |
2011-12-15 |
Auspex Pharmaceuticals, Inc. |
Benzazepine inhibitors of gamma-secretase
|
TW201118102A
(en)
|
2009-07-29 |
2011-06-01 |
Organon Nv |
Hydroxyasenapine compounds, derivatives thereof and pharmaceutical compositions comprising same
|
EP2473166A2
(en)
|
2009-08-31 |
2012-07-11 |
Eric B. Schneider |
Treatment and prevention of secondary injury after trauma or damage to the central nervous system
|
CA2777843A1
(en)
|
2009-10-16 |
2011-04-21 |
University Of South Florida |
Treatment of suicidal ideation or behavior using inhibitors of nicotinic acetylcholine receptors
|
WO2011057199A1
(en)
|
2009-11-06 |
2011-05-12 |
Adenios, Inc. |
Compositions for treating cns disorders
|
US9629920B2
(en)
|
2009-12-18 |
2017-04-25 |
Exodos Life Sciences Limited Partnership |
Methods and compositions for stable liquid drug formulations
|
CA2785056A1
(en)
|
2009-12-22 |
2011-07-21 |
Pondera Biotechnologies, LLC |
Methods and compositions for treating distress dysfunction and enhancing safety and efficacy of specific medications
|
AR079814A1
(es)
|
2009-12-31 |
2012-02-22 |
Otsuka Pharma Co Ltd |
Compuestos heterociclicos, composiciones farmaceuticas que los contienen y sus usos
|
WO2011085188A1
(en)
|
2010-01-07 |
2011-07-14 |
Eurand, Inc. |
Pharmaceutical compositions comprising anti-psychotic drugs
|
US20110166194A1
(en)
|
2010-01-07 |
2011-07-07 |
Alkermes, Inc. |
Asenapine Prodrugs
|
AU2010339689B2
(en)
|
2010-01-07 |
2015-02-19 |
Alkermes Pharma Ireland Limited |
Quaternary ammonium salt prodrugs
|
ITMI20100260A1
(it)
|
2010-02-19 |
2011-08-20 |
Giulio Scigliano |
Composizione farmaceutica contenente un farmaco per ridurre gli effetti collaterali dei farmaci antipsicotici
|
WO2011105492A1
(ja)
|
2010-02-24 |
2011-09-01 |
久光製薬株式会社 |
経皮吸収製剤
|
WO2011105486A1
(ja)
|
2010-02-24 |
2011-09-01 |
久光製薬株式会社 |
貼付剤
|
WO2011107855A2
(en)
|
2010-03-04 |
2011-09-09 |
Torrent Pharmaceuticals Limited |
Sustained release oral liquid suspension dosage form
|
US20130245253A1
(en)
|
2010-03-26 |
2013-09-19 |
Department Of Veterans Affairs |
Conjugated Neuroactive Steroid Compositions And Methods Of Use
|
US20130053357A1
(en)
|
2010-04-28 |
2013-02-28 |
Hisamitsu Pharmaceutical Co., Inc. |
Skin irritation suppressant and transdermal preparation
|
WO2011143755A1
(en)
|
2010-05-21 |
2011-11-24 |
Serdar Dursun |
Compositions and methods of treating schizophrenia
|
CN101851242B
(zh)
|
2010-05-25 |
2013-07-24 |
上海皓元生物医药科技有限公司 |
阿塞那平中间体的制备方法
|
WO2011159903A2
(en)
|
2010-06-18 |
2011-12-22 |
Dr. Reddy's Laboratories Ltd. |
Asenapine maleate
|
US8653280B2
(en)
|
2010-07-29 |
2014-02-18 |
Laboratories Lesvi, S.L. |
Process for the preparation of asenapine
|
EP2616538A4
(en)
|
2010-09-16 |
2014-03-05 |
Univ Cornell |
USE OF ADENOSINE RECEPTOR SIGNALS FOR MODULATING THE PERMEABILITY OF THE BLOOD-BRAIN BARRIER
|
WO2012038975A2
(en)
|
2010-09-22 |
2012-03-29 |
Msn Laboratories Limited |
Process for the preparation of (3ars,12brs)-5-chloro-2-methyl-2,3,3a12b-tetrahydro-1hdibenzo[2,3:6,7] oxepino [4,5-c]pyrrole maleate and it's pharmaceutical composition thereof
|
US20130274466A1
(en)
|
2010-09-27 |
2013-10-17 |
Alphora Research Inc. |
Process for the preparation of tetracyclic derivatives and intermediate products used in the process
|
WO2012065102A2
(en)
|
2010-11-12 |
2012-05-18 |
Promentis Pharmaceuticals, Inc. |
S-t-butyl protected cysteine di-peptide analogs and related compounds
|
WO2012065110A2
(en)
|
2010-11-12 |
2012-05-18 |
Promentis Pharmaceuticals, Inc. |
S-protected cysteine analogs and related compounds
|
WO2012066565A2
(en)
|
2010-11-16 |
2012-05-24 |
Cadila Healthcare Limited |
Asenapine maleate amorphous and crystalline form and process for preparation thereof
|
BR112013012156A2
(pt)
|
2010-11-17 |
2017-12-05 |
Hexal Ag |
sistema terapêutico transdérmico e método de produção de um sistema terapêutico transdérmico
|
JP5687354B2
(ja)
|
2010-11-26 |
2015-03-18 |
ユニバーシティ・オブ・ザ・ウィットウォータースランド・ヨハネスブルグUniversity Of The Witwatersrand, Johannesburg |
薬物送達デバイス
|
EP2642988A1
(en)
|
2010-11-26 |
2013-10-02 |
Ramot at Tel-Aviv University Ltd |
Method and composition for weight-gain management
|
EP2468750A1
(en)
|
2010-12-13 |
2012-06-27 |
Chemo Ibérica, S.A. |
Polymorphic forms of asenapine maleate and processes for their preparation
|
WO2012088441A1
(en)
|
2010-12-23 |
2012-06-28 |
Alkermes, Inc. |
Multi- api loading prodrugs
|
ES2575544T3
(es)
|
2010-12-24 |
2016-06-29 |
Medichem, S.A. |
Procedimientos para la preparación de 5-cloro-2-metil-2,3,3a,12b-tetrahidro-1H-dibenzo[2,3:6,7]oxepino[4,5-c]pirrol
|
US9737531B2
(en)
|
2012-07-12 |
2017-08-22 |
Glytech, Llc |
Composition and method for treatment of depression and psychosis in humans
|
WO2012114325A1
(en)
|
2011-02-23 |
2012-08-30 |
Mapi Pharma Limited |
Polymorphs of asenapine maleate
|
WO2012123325A1
(en)
|
2011-03-11 |
2012-09-20 |
Medichem S.A. |
NEW CRYSTAL FORMS OF THE SALT OF TRANS-5-CHLORO-2-METHYL-2,3,3A,12b-TETRAHYDRO-1H-DIBENZO[2,3:6,7]OXEPINO[4,5-c]PYRROLE WITH MALEIC ACID
|
CA2833474C
(en)
|
2011-04-18 |
2017-09-19 |
Hisamitsu Pharmaceutical Co., Inc. |
Method for producing patch, and patch
|
ITMI20110734A1
(it)
|
2011-05-02 |
2012-11-03 |
Olon Spa |
Sali cristallini di asenapina
|
EP2524921A1
(en)
|
2011-05-17 |
2012-11-21 |
Sandoz AG |
Novel Crystalline Salts of Asenapine
|
EP2524919A1
(en)
|
2011-05-17 |
2012-11-21 |
Sandoz AG |
Novel crystalline salts of Asenapine with organic Di-acids and Tri-acids
|
EP2524920A1
(en)
|
2011-05-17 |
2012-11-21 |
Sandoz AG |
Novel Crystalline Asenapine Hydrochloride Salt Forms
|
WO2012156676A1
(en)
|
2011-05-18 |
2012-11-22 |
Laboratorios Lesvi S.L. |
Monoclinic crystalline form of asenapine maleate with a specific particle size distribution
|
JP6014656B2
(ja)
|
2011-05-18 |
2016-10-25 |
ラビラトリオス レスビ エス エレ |
化合物の多形体
|
DE102011076653A1
(de)
|
2011-05-27 |
2012-11-29 |
Acino Ag |
Transdermales therapeutisches System enthaltend Buprenorphin und eine alpha-Hydroxysäure
|
KR20130002292A
(ko)
|
2011-06-28 |
2013-01-07 |
주식회사 비보존 |
다중 타겟팅의 상승 효과를 유발하는 유효물질의 조합 및 그 용도
|
AR086798A1
(es)
|
2011-06-29 |
2014-01-22 |
Otsuka Pharma Co Ltd |
Derivados quinazolinicos utiles para tratar trastornos del sistema nervioso central y composiciones farmaceuticas que los contienen
|
WO2013024492A2
(en)
|
2011-07-01 |
2013-02-21 |
Megafine Pharma (P) Ltd. |
A process for the preparation of asenapine and novel salts thereof
|
US9145421B2
(en)
|
2011-07-20 |
2015-09-29 |
Ranbaxy Laboratories Limited |
Process for the preparation of asenapine maleate
|
CA2842106A1
(en)
|
2011-07-28 |
2013-01-31 |
Promentis Pharmaceuticals, Inc. |
Cysteine prodrugs
|
AR082640A1
(es)
*
|
2011-08-25 |
2012-12-19 |
Amarin Technologies S A |
Un dispositivo para la administracion transdermal de compuestos alcalinos susceptibles a la degradacion en su forma no salificada
|
WO2013035109A1
(en)
|
2011-09-08 |
2013-03-14 |
Mylan Laboratories Ltd |
Improved process for the preparation of asenapine maleate
|
US20150224120A1
(en)
|
2011-09-14 |
2015-08-13 |
Catherine Clelland |
Compositions and methods for treating hyperprolinemia-associated mental disorders
|
EP2572703A1
(en)
|
2011-09-21 |
2013-03-27 |
Hexal AG |
Compressed oral dosage form for asenapine maleate
|
WO2013041604A1
(en)
|
2011-09-21 |
2013-03-28 |
Sandoz Ag |
Crystal form of asenapine maleate
|
WO2013061247A1
(en)
|
2011-10-24 |
2013-05-02 |
Alembic Pharmaceuticals Limited |
Novel process for the preparation of asenapine
|
US8980298B2
(en)
|
2011-10-24 |
2015-03-17 |
Braeburn Pharmaceuticals Bvba Sprl |
Implantable tizanidine compositions and methods of treatment thereof
|
US20140350081A1
(en)
|
2011-11-04 |
2014-11-27 |
Purdue Research Foundation |
Insect g-coupled receptors useful as targets for insecticides and compounds and reagents identified using the same
|
WO2013080069A1
(en)
|
2011-11-28 |
2013-06-06 |
Ranbaxy Laboratories Limited |
Process for the preparation of asenapine intermediate
|
US20130143867A1
(en)
|
2011-12-02 |
2013-06-06 |
Sychroneuron Inc. |
Acamprosate formulations, methods of using the same, and combinations comprising the same
|
WO2013114400A2
(en)
|
2012-01-20 |
2013-08-08 |
Rubicon Research Private Limited |
Compressed pharmaceutical compositions of atypical antipsychotics
|
CN103254201B
(zh)
|
2012-02-21 |
2016-04-13 |
四川科伦药物研究有限公司 |
一种阿塞那平的制备方法
|
SI2825208T1
(sl)
|
2012-03-14 |
2017-10-30 |
Levicept Ltd. |
P75ntr nevrotrofin vezavni protein za terapevtsko rabo
|
DE102012205493A1
(de)
|
2012-04-03 |
2013-10-10 |
Acino Ag |
Einen Dopamin-Agonisten enthaltendes transdermales Applikationssystem
|
CA2908622A1
(en)
|
2012-04-18 |
2013-10-24 |
Hemoshear, Llc |
In vitro model for pathological or physiologic conditions
|
KR20130120648A
(ko)
|
2012-04-26 |
2013-11-05 |
에스에프씨 주식회사 |
벤조사이클로플루오렌계 화합물 및 이를 포함하는 유기전계발광소자
|
US20150141274A1
(en)
|
2012-05-09 |
2015-05-21 |
The Rockefeller University |
Methods and Compositions for Activity Dependent Transcriptome Profiling
|
WO2013190481A1
(en)
|
2012-06-21 |
2013-12-27 |
Alembic Pharmaceuticals Limited |
Process for preparing asenapine and salts of intermediates thereof
|
JP6005741B2
(ja)
*
|
2012-07-26 |
2016-10-12 |
久光製薬株式会社 |
貼付剤及びその製造方法
|
US8986677B2
(en)
|
2012-07-30 |
2015-03-24 |
Pop Test Cortisol Llc |
Therapeutic compositions and methods
|
EP2900220B1
(en)
|
2012-09-28 |
2018-12-12 |
Delpor, Inc. |
Device and methods for sustained release of antipsychotic medications
|
ITMI20121810A1
(it)
|
2012-10-24 |
2014-04-25 |
Chemo Iberica Sa |
Poliformi di maleato di asenapina e processo per la loro preparazione
|
JOP20210047A1
(ar)
|
2012-10-25 |
2017-06-16 |
Otsuka Pharma Co Ltd |
عامل وقائي و/أو علاجي للأعراض السلوكية والنفسية المصحوبة بمرض تنكسي عصبي أو الأعراض الإندفاعية المصحوبة بمرض ذهني، يحتوي على بريكسبيرازول أو ملحه
|
WO2014078377A1
(en)
|
2012-11-14 |
2014-05-22 |
Agenebio, Inc. |
Methods and compositions for treating schizophrenia
|
WO2014078568A1
(en)
|
2012-11-14 |
2014-05-22 |
The Johns Hopkins University |
Methods and compositions for treating schizophrenia
|
WO2014080378A1
(en)
|
2012-11-26 |
2014-05-30 |
University Of Cape Town |
Phenothiazine derivatives and their use against tuberculosis
|
JP2014105205A
(ja)
|
2012-11-30 |
2014-06-09 |
Medical Front Co Ltd |
医用貼付剤
|
WO2014090386A1
(en)
|
2012-12-11 |
2014-06-19 |
Alfred E. Tiefenbacher (Gmbh & Co. Kg) |
Orally disintegrating tablet containing asenapine
|
CA2895129C
(en)
|
2012-12-20 |
2022-07-05 |
Sanford-Burnham Medical Research Institute |
Quinazoline neurotensin receptor 1 agonists and uses thereof
|
CA2896347A1
(en)
|
2012-12-28 |
2014-07-03 |
Noven Pharmaceuticals, Inc. |
Multi-polymer compositions for transdermal drug delivery
|
CN103893139B
(zh)
|
2012-12-28 |
2018-06-08 |
石药集团中奇制药技术(石家庄)有限公司 |
一种阿塞那平组合物及其制备方法
|
TWI646091B
(zh)
|
2012-12-28 |
2019-01-01 |
日商衛斯克慧特股份有限公司 |
鹽類及晶形
|
CN103965206A
(zh)
|
2013-01-29 |
2014-08-06 |
北京京卫燕康药物研究所有限公司 |
一种阿色纳品马来酸盐的新晶型及制备方法
|
US10154856B2
(en)
|
2013-02-06 |
2018-12-18 |
Mark SILLENDER |
Therapeutic substance transfer catheter and method
|
WO2014127786A1
(en)
|
2013-02-22 |
2014-08-28 |
Zentiva, K.S. |
Orally disintegrating pharmaceutical composition comprising asenapine
|
WO2014165136A1
(en)
|
2013-03-12 |
2014-10-09 |
Antares Pharma, Inc. |
Constant volume prefilled syringes and kits thereof
|
US20140271923A1
(en)
|
2013-03-14 |
2014-09-18 |
Christopher Brian Reid |
Compositions & formulations for preventing and treating chronic diseases that cluster in patients such as cardiovascular disease, diabetes, obesity, polycystic ovary syndrome, hyperlipidemia and hypertension, as well as for preventing and treating other diseases and conditions
|
WO2014160155A2
(en)
|
2013-03-14 |
2014-10-02 |
Endo Pharmaceuticals Solutions Inc. |
Implantable drug delivery compositions comprising non-polymeric sorption enhancers and methods of treatment thereof
|
WO2014152965A2
(en)
|
2013-03-14 |
2014-09-25 |
The Children's Hospital Of Philadelphia |
Schizophrenia-associated genetic loci identified in genome wide association studies and use thereof as novel therapeutic targets
|
WO2014160167A1
(en)
|
2013-03-14 |
2014-10-02 |
Endo Pharmaceuticals Solutions Inc. |
Implantable drug delivery compositions comprising aromatic polyurethanes and methods of treatment thereof
|
US20140276479A1
(en)
*
|
2013-03-14 |
2014-09-18 |
Noven Pharmaceuticals, Inc. |
Transdermal drug delivery system with overlay
|
WO2014160026A2
(en)
|
2013-03-14 |
2014-10-02 |
Endo Pharmaceuticals Solutions Inc. |
Implantable drug delivery compositions comprising sugar-based sorption enhancers and methods of treatment thereof
|
US20140287529A1
(en)
|
2013-03-15 |
2014-09-25 |
Ameritox, Ltd. |
Methods of normalizing measured drug concentrations and testing for potential non-compliance with a drug treatment regimen
|
CA2909633A1
(en)
|
2013-03-15 |
2014-09-18 |
Als Mountain Llc |
Pharmaceutical composition comprising an ampk activator and a serotonergic agent and methods of use thereof
|
US20140274764A1
(en)
|
2013-03-15 |
2014-09-18 |
Pathway Genomics Corporation |
Method and system to predict response to treatments for mental disorders
|
EP2968248A4
(en)
*
|
2013-03-15 |
2016-08-31 |
Nal Pharmaceutical Group Ltd |
TRANSDERMAL ACTIVE COMPOSITION SYSTEM WITH RIVASTIGMIN
|
AR095259A1
(es)
|
2013-03-15 |
2015-09-30 |
Noven Pharma |
Composiciones y métodos para la administración transdérmica de fármacos de amina terciaria
|
JP6129632B2
(ja)
|
2013-04-24 |
2017-05-17 |
帝國製薬株式会社 |
貼付剤
|
JP6559121B2
(ja)
*
|
2013-06-04 |
2019-08-14 |
エルテーエス ローマン テラピー−ジステーメ アーゲー |
経皮送達システム
|
EP3003297A4
(en)
|
2013-06-05 |
2017-04-19 |
Synchroneuron Inc. |
Acamprosate formulations, methods of using the same, and combinations comprising the same
|
WO2014207664A2
(en)
|
2013-06-28 |
2014-12-31 |
Alembic Pharmaceuticals Limited |
Stable pharmaceutical composition of asenapine
|
WO2015027342A1
(en)
|
2013-08-30 |
2015-03-05 |
Mcmaster University |
Microgel compositions for delivery of substances to the brain
|
CN104447770A
(zh)
|
2013-09-12 |
2015-03-25 |
天津市汉康医药生物技术有限公司 |
阿塞那平化合物
|
CN104447771A
(zh)
|
2013-09-12 |
2015-03-25 |
天津市汉康医药生物技术有限公司 |
一种稳定的马来酸阿塞那平化合物
|
US10098893B2
(en)
|
2013-10-03 |
2018-10-16 |
Northwestern University |
Methods of administering a trace amine-associated receptor 1 (TAAR1) agonist to patients having the minor allele of the single nucleotide polymorphism rs2237457
|
US9757330B2
(en)
|
2013-10-18 |
2017-09-12 |
Industrial Technology Research Institute |
Recipe for in-situ gel, and implant, drug delivery system formed thereby
|
IN2013MU03596A
(es)
|
2013-11-18 |
2015-07-24 |
Piramal Entpr Ltd |
|
KR102421656B1
(ko)
|
2013-12-03 |
2022-07-15 |
인트라-셀룰라 써래피스, 인코퍼레이티드. |
신규한 방법
|
US20160303102A1
(en)
|
2013-12-05 |
2016-10-20 |
Alrise Biosystems Gmbh |
Process for the production of drug formulations for oral administration
|
WO2015087927A1
(ja)
*
|
2013-12-12 |
2015-06-18 |
久光製薬株式会社 |
カバー材付き貼付剤及びカバー材付き貼付剤キット
|
CN103772400A
(zh)
|
2014-01-07 |
2014-05-07 |
万特制药(海南)有限公司 |
反式-5-氯-2,3,3a,12b-四氢-1H-二苯并[2,3:6,7]氧杂卓并[4,5-c]吡咯的制备方法
|
CN103772402A
(zh)
|
2014-01-07 |
2014-05-07 |
万特制药(海南)有限公司 |
一种新的阿塞那平马来酸盐粗品精制方法
|
CN103772401A
(zh)
|
2014-01-07 |
2014-05-07 |
万特制药(海南)有限公司 |
11-氯-2,3,3a,12b-四氢-2-甲基-1H-二苯并[2,3:6,7]氧杂卓并[4,5-c]吡咯-1-酮的一种新精制方法
|
CN103760280A
(zh)
|
2014-01-10 |
2014-04-30 |
万特制药(海南)有限公司 |
一种用液相色谱法分离测定阿塞那平中间体有关物质的方法
|
JP6718376B2
(ja)
|
2014-02-07 |
2020-07-08 |
ニューロクライン バイオサイエンシーズ,インコーポレイテッド |
抗精神病薬物およびvmat2阻害剤を含む医薬組成物およびその使用
|
US20170007537A1
(en)
|
2014-02-18 |
2017-01-12 |
Hetero Research Foundation |
Pharmaceutical compositions of asenapine
|
CA2949480A1
(en)
|
2014-02-24 |
2015-08-27 |
Urigen Pharmaceuticals, Inc. |
Compositions of pentosan polysulfate salts for oral administration and methods of use
|
WO2015127558A1
(en)
|
2014-02-28 |
2015-09-03 |
UNIVERSITé LAVAL |
Methods and uses for inducing or facilitating micturition in a patient in need thereof
|
WO2015127556A1
(en)
|
2014-02-28 |
2015-09-03 |
UNIVERSITé LAVAL |
Methods and uses for inducing or facilitating defecation in a patient in need thereof
|
JP6588919B2
(ja)
|
2014-02-28 |
2019-10-09 |
センター フォー アディクション アンド メンタル ヘルスCentre For Addiction And Mental Health |
抗精神病薬により誘導される体重増加の処置および予防のための組成物および方法
|
CN103864802B
(zh)
|
2014-03-31 |
2016-08-17 |
四川科伦药业股份有限公司 |
马来酸阿塞那平的制备方法
|
CN104974168B
(zh)
|
2014-04-02 |
2019-01-04 |
洋浦慧谷医药有限公司 |
阿塞那平的制备方法以及用于制备阿塞那平的中间体
|
CN104974167B
(zh)
|
2014-04-02 |
2019-01-04 |
洋浦慧谷医药有限公司 |
阿塞那平的制备方法以及用于制备阿塞那平的中间体
|
EP3125892A4
(en)
|
2014-04-04 |
2017-12-27 |
Intra-Cellular Therapies, Inc. |
Organic compounds
|
BR112016023162B1
(pt)
|
2014-04-04 |
2022-11-29 |
Intra-Cellular Therapies, Inc |
Compostos orgânicos gama-carbolinas, composições farmacêuticas compreendendo os ditos compostos e uso dos mesmos no tratamento ou na profilaxia de transtornos de sistema nervoso central
|
CN104000800A
(zh)
|
2014-04-28 |
2014-08-27 |
万特制药(海南)有限公司 |
马来酸阿塞那平口腔速溶膜剂及其制备方法
|
ES2954087T3
(es)
|
2014-05-20 |
2023-11-20 |
Lts Lohmann Therapie Systeme Ag |
Sistema de administración transdérmica que incluye un mediador de interfase
|
JP6895755B2
(ja)
|
2014-05-20 |
2021-06-30 |
エルテーエス ローマン テラピー−ジステーメ アーゲー |
経皮送達システムにおける活性薬剤の放出を調節するための方法
|
US9662392B2
(en)
|
2014-06-03 |
2017-05-30 |
Pop Test Abuse Deterrent Technology Llc |
Drug device configured for wireless communication
|
US10179776B2
(en)
|
2014-06-09 |
2019-01-15 |
Intra-Cellular Therapies, Inc. |
Compounds and methods of use to treat schizophrenia
|
CN104133010B
(zh)
|
2014-07-01 |
2019-11-29 |
北京万全德众医药生物技术有限公司 |
高效液相色谱法分离分析阿西马朵林中间体及光学异构体
|
CN104133012B
(zh)
|
2014-07-02 |
2020-01-07 |
北京万全德众医药生物技术有限公司 |
一种高效液相色谱法测定马来酸阿塞那平消旋体的方法
|
ES2784756T3
(es)
*
|
2014-07-18 |
2020-09-30 |
Buzzz Pharmaceuticals Ltd |
Parche transdérmico opioide/antagonista de opioides disuasivo del abuso
|
CN104098580B
(zh)
|
2014-07-22 |
2016-04-13 |
成都百裕科技制药有限公司 |
一种阿塞那平关键中间体的制备方法
|
AR101358A1
(es)
|
2014-07-31 |
2016-12-14 |
Noven Pharma |
Composiciones de polímeros acrílicos que contienen siliconas para la administración transdérmica de fármacos
|
ES2562684B1
(es)
|
2014-08-04 |
2017-02-06 |
Consejo Superior De Investigaciones Científicas (Csic) |
Método de monitorización de tratamiento antipsicótico
|
WO2016023658A1
(en)
|
2014-08-14 |
2016-02-18 |
Alrise Biosystems Gmbh |
Injectable formulations of asenapine
|
JP2016056142A
(ja)
|
2014-09-11 |
2016-04-21 |
第一三共株式会社 |
Pde10a阻害薬と抗精神病薬の組み合わせ
|
CN104297366A
(zh)
|
2014-09-24 |
2015-01-21 |
万特制药(海南)有限公司 |
马来酸阿塞那平及其杂质的液相分析方法
|
PT3206678T
(pt)
|
2014-10-14 |
2020-03-23 |
Sculpt B V |
Escultura corporal
|
AU2015335375B2
(en)
|
2014-10-24 |
2020-09-10 |
Launx Biomedical Co., Ltd. |
Use of azelnidipine in preparing medicinal composition for treating cancers
|
EP3020782B1
(en)
|
2014-11-11 |
2018-08-01 |
SFC Co., Ltd. |
An electroluminescent compound and an electroluminescent device comprising the same
|
US20160235677A1
(en)
|
2014-11-25 |
2016-08-18 |
Nanocopoeia, Llc. |
Method of converting a crystalline compound to an amorphous compound, method of increasing the solubility of a crystalline compound in a biorelevant fluid, and nanoparticles that achieve supersaturation
|
CA2969425A1
(en)
|
2014-12-01 |
2016-06-09 |
The Feinstein Institute For Medical Research |
Use of striatal connectivity patterns for evaluating antipsychotic agents
|
EP3227680A4
(en)
|
2014-12-05 |
2018-05-16 |
Myriad Genetics, Inc. |
Biomarkers for distinguishing mood disorders
|
EP3031458A1
(en)
|
2014-12-09 |
2016-06-15 |
Iproteos S.L. |
Use of 1-[(2-phenylcycloprop-1-yl)carbonyl]-2-[(1,3-thiazolidin-3-yl)carbonyl]perhydroindole in the treatment of schizophrenia-associated cognitive deficits
|
US9656441B2
(en)
*
|
2015-01-08 |
2017-05-23 |
Alfred E. Tiefenbacher ( Gmbh & Co. Kg) |
Transdermal patch
|
WO2016114655A1
(en)
|
2015-01-12 |
2016-07-21 |
Ry Pharma B.V. |
Treating neuromuscular or neurologic disease through reducing gabaergic and/or glycinergic inhibitory neurotransmitter overstimulation
|
EP3251663A1
(en)
|
2015-01-30 |
2017-12-06 |
Toyo Ink Sc Holdings Co., Ltd. |
Adhesive patch
|
HUE059559T2
(hu)
|
2015-02-25 |
2022-12-28 |
Univ California |
5HT agonisták az epilepsziás rendellenességek kezelésére
|
CN107427472B
(zh)
|
2015-03-02 |
2021-04-30 |
久光制药株式会社 |
贴附剂
|
KR20160107610A
(ko)
|
2015-03-04 |
2016-09-19 |
한국과학기술원 |
대사 질환의 예방 또는 치료용 조성물
|
ITUB20150635A1
(it)
|
2015-04-14 |
2016-10-14 |
Giuseppe Lotito |
Uso di un inibitore dell’aceticolinesterasi e composizioni farmaceutiche contenenti detto inibitore.
|
WO2016170102A1
(en)
|
2015-04-22 |
2016-10-27 |
Cemm - Forschungszentrum Für Molekulare Medizin Gmbh |
Combination of an antiandrogen with a vitamin k antagonist or with a gamma -glutamyl carboxylase inhibitor for the therapy of androgen receptor positive cancer
|
US20190055603A1
(en)
|
2015-04-28 |
2019-02-21 |
Proove Biosciences, Inc. |
System and method for processing genotype information relating to drug metabolism
|
ES2598248B1
(es)
|
2015-06-26 |
2017-12-18 |
Centro De Investigación Biomédica En Red |
Método in vitro y kit para el pronóstico o predicción de la respuesta al tratamiento con agentes antipsicóticos por parte de pacientes que han sufrido un primer episodio psicótico
|
US10806705B2
(en)
*
|
2015-07-27 |
2020-10-20 |
Hisamitsu Pharmaceutical Co., Inc. |
Asenapine-containing patch
|
WO2017018321A1
(ja)
*
|
2015-07-27 |
2017-02-02 |
久光製薬株式会社 |
アセナピン含有貼付剤の製造方法
|
CN105566336A
(zh)
|
2016-01-08 |
2016-05-11 |
万特制药(海南)有限公司 |
一种制备阿塞那平去甲基杂质的新方法
|
CN105693735A
(zh)
|
2016-01-15 |
2016-06-22 |
万特制药(海南)有限公司 |
马来酸阿塞那平一种制备方法
|
JP6556873B2
(ja)
|
2016-01-28 |
2019-08-07 |
久光製薬株式会社 |
経皮吸収製剤
|
JP6658201B2
(ja)
|
2016-03-28 |
2020-03-04 |
東洋インキScホールディングス株式会社 |
貼付剤
|
KR20160108258A
(ko)
|
2016-06-20 |
2016-09-19 |
한국과학기술원 |
대사 질환의 예방 또는 치료용 조성물
|
EP3490559A1
(en)
|
2016-07-27 |
2019-06-05 |
Corium International, Inc. |
Transdermal delivery systems with pharmacokinetics bioequivalent to oral delivery
|
CN115813887A
(zh)
|
2016-12-20 |
2023-03-21 |
罗曼治疗系统股份公司 |
包含阿塞那平的透皮治疗系统
|